Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 6Phase 3 3Phase NA 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 168Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Recurrence 28Leukemia 24Vomiting 23Neoplasms, Plasma Cell 20Lymphoma 18Neoplasms 16Nausea 13Burkitt Lymphoma 11Prostatic Neoplasms 8Immunoglobulin Light-chain Amyloidosis 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Follicular 5Lung Neoplasms 5Hodgkin Disease 5Ovarian Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Leukemia, Biphenotypic, Acute 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Paraproteinemias 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

Melphalan 3Dexamethasone 3Bortezomib 3daratumumab 1Filgrastim 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Amyloidosis × Dexamethasone × Clear all
NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Janssen Research & Development, LLC

Phase 3 Completed
416 enrolled 28 charts 2 FDA
Plasma cell

Amyloidosis

NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

National Cancer Institute (NCI)

Phase 3 Completed
11 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01998503 2013-11-29

Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

Nanjing University School of Medicine

Phase 3 Completed
56 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡